Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement.
The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience.
To view the multimedia release go to:
http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Altimetrik, a business transformation and technology solutions company is unveiling advanced IoT solutions that are set to revolutionize the manufacturing industry.
Manufacturing industry is faced with the challenge of digitally connecting its assets with systems and people, engineering and acting upon the data on the floor to achieve predictive maintenance, precision monitoring & remote management. Altimetrik's Enterprise IoT capabilities make operational intelligence real by connecting machine data to newer business insights & driving meaningful outcomes. Altimetrik has made significant investments in creating IoT specific Research & Innovation Labs which’ve helped the company become a frontrunner in IoT consulting and execution. Altimetrik has been identified among leading IoT solution providers for manufacturing by IDC
Altimetrik is among the new breed of technology companies driving its business model based on the three global mega trends of modernization – Digital, Connected Solutions and Consumer Technologies.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7772051-altimetrik-future-of-enterprise-internet/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
A new crash test program from the Insurance Institute for Highway Safety aims to ensure that manufacturers pay attention to the safety of front passengers as well as drivers.
The test was developed after it became clear that some manufacturers were giving short shrift to the right side of the vehicle when it comes to small overlap front crash protection. A good or acceptable passenger-side rating will be required to qualify for the Institute’s 2018 TOP SAFETY PICK+ award.
The first test group in the passenger-side small overlap front test program did better overall than vehicles IIHS previously evaluated for research. Ten out of 13 midsize cars tested earn a good rating, while one is acceptable and two earn a marginal rating.
In contrast with a group of 2014-16 model small SUVs tested for research, none of the 2017-18 midsize cars had a poor or marginal structural rating. Instead, the biggest problem in the new group was inconsistent airbag protection in five cars, which would put passengers’ heads at risk.
After only 16 weeks of existence, foetuses hear and respond to music as long as it is emitted from their mother’s vagina. Foetuses respond to this stimulus by opening their mouths and pulling their tongues out as far as possible, making vocalisation movements – prior to the acquisition of language.
This is the main conclusion of the study conducted by the team of Institut Marquès, which boasts the collaboration of Alberto Prats, Professor of Anatomy and Human Embryology of the Faculty of Medicine of the University of Barcelona.
The study, entitled “Foetal facial expression in response to intravaginal music emission”, is published this week in the journal Ultrasound of the British Medical Ultrasound Society (BMUS).
According to Dr. Marisa López-Teijón, the Head of Assisted Reproduction at Institut Marquès and the principal researcher and author of the clinical study: “We have discovered that the formula for foetuses to hear like us is to emit music from the mother’s vagina. They barely hear the sound that reaches them through their mother’s abdomen: the soft tissues of the abdomen and the inside of the mother’s body absorb the soundwaves”.
To view the multimedia release go to:
http://www.multivu.com/players/English/7647351-how-foetuses-hear-musical-stimuli/
When asked how they feel about mixing their work and personal lives, 58% of Generation Mobile workers feel guilty, according to new research from MobileIron. The MobileIron Gen M Survey, a global study of more than 3,500 full- and part-time professionals who use a mobile device for work, highlights an emerging demographic in the workplace: Generation Mobile or “Gen M.” The study found that Gen M, which is composed of mobile workers who are either men age 18-34 or people with children under age 18 in their households, relies more heavily on mobile technologies than the general population to mix their work and personal activities.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7423151-mobileiron-gen-m-study-mobile-guilt/
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
https://youtu.be/_HT-llQ-kmw If you’re a business owner trying to find ways to increase conversions or security or both on your site, you may have found there’s a lot of buzz about how trust seals can help your site. It’s pretty much a given that to have at least a shot at winning the ecommerce game, your site needs a trust seal. But choosing a trust seal that’s both right for you and from a company that can back up its claims takes a little research.
Online Learning Guideline process.
ACRI is the only institute to incorporate activity based learning methodology. Our students are placed in highly reputed firms and have been recognized for their extensive knowledge in the field of Clinical Research
Reach us :
acriindia.com/about-acri
